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Symptoms of the urinary bladder overactivity,
with an impairment of the filling phase and its
reduced compliance, are common problems of the
lower urinary tract. According to the currently
applied terminology, disorders suggesting some
dysfunctions of the bladder filling phase (urinary
urgency) and micturition (polyuria, frequent passage
of small amounts of urine, urine incontinence), con-
stitute a basis for diagnosis of the overactive bladder
syndrome (OAB) (1, 2). 
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Abstract: Signs and symptoms of secondary overactive bladder (OAB) are observed both in course of infra-
vesical obstruction of urine outflow in patients with benign prostatic hyperplasia, and as a result of develop-
ment of hemorrhagic cystitis (HC) following administration of cyclophosphamide (CP). Non-steroidal anti-
inflammatory drugs (NSAIDs) alleviate symptoms of bladder overactivity reducing local synthesis of
prostaglandins (PGs), but precise effects of those agents on functions of the autonomic nervous system (ANS)
in course of OAB remain unknown. The purpose of this study was to evaluate the effect of piroxicam-induced
prostaglandins (PGs) synthesis block on activity of the ANS in two experimental models of secondary OAB:
bladder outlet obstruction (BOO) and cyclophosphamide-induced HC (CP-HC), by heart rate variability analy-
sis (HRV). The experiment was performed on a group of rats with surgically induced 2-week BOO, and on a
group of rats that were administered CP five times, with corresponding control groups. Study animals were
given piroxicam (PRX) i.p. in two doses: 2 and 10 mg/kg b.w.
In the BOO model, PRX in both doses revealed a trend for reduction of value of all non-normalized compo-
nents of HRV. The lower PRX dose caused an increased nHF value, and PRX administered in the dose of 10
mg/kg b.w. caused an increase of the nLF value. In the CP-HC model, the lower PRX dose caused a trend for
an increase of values of all non-normalized components, and the higher dose ñ for their decrease. Both doses
of PRX in that model caused increase of the nLF value. Inhibition of PGs synthesis caused changes of ANS
function in both models of OAB. Both in BOO and in CP-HC, PGs seem to be ANS-activating factors, respon-
sible for maintenance of a high parasympathetic activity. In both models, inhibition of PGs synthesis with PRX
administered at the dose of 10 mg/kg b.w. lead to functional reconstruction of ANS, with marked sympathetic
predominance. That may contribute to reduction of the bladder contractile action and improvement of its com-
pliance in the filling period, which was demonstrated by other authors in urodynamic tests for NSAIDs.
Keywords: overactive bladder, cyclophosphamide, bladder outlet obstruction, prostaglandins, autonomic nerv-
ous system, heart rate variability
Abbreviations: ANS ñ autonomic nervous system, BOO ñ bladder outlet obstruction, BPH ñ benign prostatic
hyperplasia, BWW ñ bladder wet weight, COX ñ cyclooxygenase, CP ñ cyclophosphamide, CP-HC ñ
cyclophosphamide-induced hemorrhagic cystitis, HF ñ high frequency (HRV spectral, non-normalized compo-
nent), HRV ñ heart rate variability, LF ñ low frequency (HRV spectral, non-normalized component), nHF ñ
normalized high hrequency (HRV spectral, normalized component), nLF ñ normalized low frequency (HRV
spectral, normalized component), NSAIDs ñ non steroidal antiinflammatory drugs, OAB ñ overactive bladder,
PGs ñ prostaglandins, PRX ñ piroxicam, rMSSD ñ the square root of the mean squared difference of succes-
sive normal-normal (R-R) intervals, R-R ñ an interval between two subsequent R waves in ECG recording,
SDNN ñ standard deviation of all normal-normal (R-R) beats, TP ñ total power (HRV spectral, non-normalized
component), VLF ñ very low frequency (HRV spectral, non-normalized component)
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The disease is an idiopathic disorder, or is a
result of action of various etiological factors leading
to detrusor overcontractility with reduced filling
phase of the bladder. A general pathophysiological
description of idiopathic OAB assumes, that its
development is a result of complex disorders, both
of myogenic (abnormal electric coupling of smooth
muscle cells of the vesicular wall, contributing to
contractile overreactivity) and neurogenic character.
A precise pathophysiological description of idio-
pathic OAB exceeds the framework of this paper,
and all necessary information may be found in
numerous reviews in that area (3ñ5), also published
by us (6). Bladder overactivity is also observed in
course of various organic disorders of the lower uri-
nary tract. Symptoms of OAB occur in patients
treated with cytostatic alkylating drugs belonging to
the group of oxazaphosphorins (e.g., cyclophos-
phamide), accompanying symptoms of hemorrhagic
cystitis (HC; cyclophosphamide-induced HC; CP-
HC). The pathogenesis of hemorrhagic cystitis is
associated with development of the bladder inflam-
matory condition ñ that, according to the OAB neu-
rogenic theory, is co-responsible for changing the
activity of afferent fibres and, at the same time, the
efferent control of the bladder function. The key
pathogenetic factor is release of acrolein (as a result
of cyclophosphamide metabolism in the bladder), as
a factor initiating some complex immunological-
inflammatory changes, with overproduction of 
NF-κB, TNF-α and overactivity of cyclooxygenases
(COX) (7, 8). The pathophysiological description of
that disorder has been also published in one of our
earlier papers (9). It is also generally known that
patients with benign prostatic hyperplasia (BPH)
also present symptoms of bladder overactivity.
Pathogenesis of bladder overactivity in BPH
patients depends on the bladder reconstruction sec-
ondary to the existing sub-vesicular block and urine
outlet obstruction (10). 
The above mentioned disorders may be rela-
tively easily studied on animal models. According to
the literature, it is possible to cause a hemorrhagic
cystitis by four intraperitoneal administration of 75
mg/kg b.w. cyclophosphamide to rats (the CP-HC
model) (11, 12). On the other hand, BPH may be
experimentally reflected by surgical creation of a
partial bladder outlet obstruction (the BOO model)
obtained by partial ligation of the proximal section
of the urethra (13, 14).
In both above mentioned cases of secondary
OAB, disturbances of the autonomic bladder control
are an additional pathogenetic element. In our previ-
ous studies, we have demonstrated that in experi-
mental CP-HC, the autonomic nervous system
(ANS) activity became reduced with a proportional
reduction of both sympathetic and parasympathetic
tonus (15). However, evaluating function of the
ANS in a 2-week BOO model in a rat, we have also
found features of reduction of global autonomic
activity, but with a reduced parasympathetic tonus
and a relative sympathetic dominance (16).
Autonomic abnormalities observed in the above
mentioned experimental models may depend on
altered paracrine function of the urothelium, being a
result of the existing inflammatory condition (CP-
HC) or excessive muscularization of the bladder due
to its overpressurising. Those disorders cause
release of prostaglandins (PGs) inside the bladder.
PGs may be co-responsible for excessive sensitiza-
tion of the bladder sensory fibres and reflexive
change of tonus of efferent fibres.
It is generally known that PGs are synthesized
de novo from arachidonic acid, in a multi-stage
process with participation of cyclooxygenase (cur-
rently identified with prostaglandin H synthase, or
prostaglandin endoperoxidase) and individual cel-
lular synthases for given prostanoids.
Cyclooxygenase is a molecular binding point for
non-steroidal anti-inflammatory drugs (NSAIDs),
that exert an analgesic and antipyretic effect by
inhibition of synthesis of prostaglandins. There are
several isoforms of cyclooxygenases (COX1 ñ con-
stitutive, COX2 ñ inflammatory-induced, COX3 ñ
central form), constituting a basis for pharmacody-
namic classification of NSAIDs, depending on their
ñ selective or non-selective ñ effect on individual
COX isoforms (17, 18).
Studies demonstrated that PGs are synthesized
locally in the bladder, both in the urothelium and the
muscular coat, indicating a complex, endocrine con-
trol of the bladder function (19, 20). Intravesical
PGs administration to rats caused reduction of the
bladder compliance and its overreactivity (21, 22).
Experimental studies demonstrated as well an
increased COX expression, both in the BOO model
(23) in response to the bladder overpressure and its
dilation, and in the model of post-cyclophosphamide
bladder injury, as a result of internal inflammation
(24). Some recent studies demonstrated also that
interstitial cells of Cajal, being an electric ìpace-
makerî of the bladder, controlling its motor function
(similarly to the digestive tract) also present a high
COX expression (both isoforms 1 and 2) (25).
Considering pleiotropic character of prostan-
oids, determination of their potential role in the
bladder overactivity in course of post-cyclophos-
phamide, hemorrhagic cystitis and benign prostatic
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hyperplasia, in context of their effect on autonomic
regulation, seems important. Therefore, the purpose
of this study was to determine an indirect ñ through
a pharmacological inhibition of prostaglandin syn-
thesis with piroxicam (PRX), a non-selective COX
inhibitor ñ effect of prostaglandins on activity of the
autonomic nervous system in experimental models
of post-cyclophosphamide, hemorrhagic cystitis (the
CP-HC model) and of a partial bladder outlet
obstruction (the BOO model). Currently, a non-
invasive evaluation of the autonomic nervous sys-
tem ñ both for clinical and experimental purposes ñ
is allowed by examination of the heart rate variabil-
ity (HRV). The HRV analysis is based on evaluation
of variability of R-R intervals in the ECG record.
Those intervals fluctuate constantly due to the fact
that the heart remains under constant autonomic
control. That parameter is a starting point for time-
domain HRV analysis, yielding some derivative
parameters. It also allows determination of a HRV
spectrum with its basic components (HRV spectral
analysis) (26, 27). Therefore, evaluating an auto-
nomic control of the heart, some indirect conclu-
sions of the ANS functional status may be drawn.
EXPERIMENTAL
The study was carried out following a consent
of the 1st Local Bioethics Committee in KrakÛw
(No. 126/2010 and 28/2013).
Animals
Sixty 6-weeks-old Wistar rats obtained from
the central animal house of the Pharmaceutical
Faculty of the Jagiellonian University Collegium
Medicum in KrakÛw were used for experiments. For
acclimatization to new living conditions, for the first
week animals were placed in five collective cages,
with unlimited access to a standard laboratory feed
(Labofeed, Kcynia) and water. Constant temperature
of 22OC was maintained in the room. At the begin-
ning of the experiment, rats were randomized into
study groups, 10 animals in each group. During the
experiment, animals in the particular group lived
together in the same cage (10 animals per cage), and
had unlimited access to water and feed.
General outline of the experiment
The experiment was run on animals with BOO,
treated (BOO + PRX) and untreated (control) with
piroxicam. Also animals with post-cyclophos-
phamide hemorrhagic cystitis were divided into two
groups: treated with piroxicam (CP-HC + PRX) and
untreated (control). Moreover, both in the BOO +
PRX, and CP-HC + PRX group we have used two
doses of PRX: 2 mg/kg b.w. and 10 mg/kg b.w.
(choice of doses was based on previously published
experimental studies using PRX (28, 29)).
Therefore, finally six study groups were formed:
BOO (control of the BOO model; group 1); BOO +
PRX 2 mg/kg b.w (group 2); BOO + PRX 10 mg/kg
b.w. (group 3); and CP-HC (control of the CP-HC
model; group 4); CP-HC + PRX 2 mg/kg b.w.
(group 5); CP-HC+PRX 10 mg/kg b.w. (group 6).
CP-HC model
In thirty animals, an experimental model of
hemorrhagic cystitis with its overactivity was creat-
ed by four (every two days ñ on the day one, three,
five and seven) intraperitoneal administrations of
cyclophosphamide ñ CP (Sigma Aldrich) ñ at the
dose of 75 mg/kg b.w. The CP solution was pre-
pared each time ex tempore before administration.
According to the literature, dosage scheme leads to
hemorrhagic cystitis following the fourth dose (11,
12). Ten animals received CP only, and formed a
control group (group 4), and other 20 rats received
additionally piroxicam (Feldene, Pfizer, ampoules
20 mg/mL) in two doses: 2 and 10 mg/kg b.w., as
described above. PRX, the same as CP, was admin-
istered intraperitoneally four times, two hours fol-
lowing the administration of CP. In the group of ani-
mals receiving 10 mg/kg b.w. PRX, four animals
died ñ therefore, only six animals were considered in
the final analysis. In the CP-HC + PRX 2 mg/kg
b.w. group one animal died, therefore HRV records
were finally obtained from 9 animals. The controls
received normal saline in volume corresponding to
the volume of PRX instead of PRX. All animals in
that group survived administration of the fourth dose
of CP, but a majority of them were in overall poor
condition. We have even observed a body weight
reduction in those animals.
BOO model
Another 30 animals had the proximal section
of urethra partially surgically ligated, in order to cre-
ate the bladder outlet obstruction. According to the
literature, a condition clinically corresponding to
BPH with bladder overactivity develops within two
weeks post the surgery (13, 14). The procedure was
conducted under pentobarbital anesthesia (Morbital,
Pu≥awy, 40 mg/kg b.w. administered i.p.).
Following the anesthesia, a medial cut was made in
the projection over the bladder. Exposed bladder
was carefully separated from the surrounding fatty
tissue, and the urethra was catheterized (polyethyl-
ene catheter, diameter 0.58 mm), ligating the proxi-
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mal section of the urethra around the catheter. After
the catheter was removed, abdominal integument
and skin were sutured in layers with standard surgi-
cal sutures (Medilen 4/0 USP; cutting needle DS2,
3/8). The surgical wound was sprayed with
neomycin and the skin was sprayed with oxycort to
minimize the risk of post-surgical infection. Two
first days after the surgery were treated as a conva-
lescence period. On the day three, PRX was admin-
istered i.p. at the dose of 2 or 10 mg/kg b.w. in both
BOO + PRX subgroups (groups 2 and 3), or normal
saline was administered at the volume correspon-
ding to the volume of PRX in the control BOO
group (group 1). PRX or normal saline were admin-
istered, similarly to CP-HC + PRX/CP-HC groups,
four times ñ on the day three, seven, eleven and fif-
teen after the surgery. Two animals in the control
BOO group did not survive the procedure.
Therefore, that group consisted finally of 8 animals.
Moreover, 2 animals treated with PRX at the dose of
2 mg/kg b.w. and 3 animals treated with PRX at the
dose of 10 mg/kg b.w. died before reception of the
final dose. Therefore, HRV records were obtained
from 8 animals in the BOO + PRX 2 mg/kg b.w.
group and from 7 animals in the BOO + PRX 10
mg/kg b.w. group.
Body weight and excreted urine volume 
measurement
On the first day of the experiment and on the
last day (the day of HRV records registration) body
weight of animals was measured in all study groups.
Moreover, on the first day of the experiment, we
measured a daily urine output in healthy animals
randomized to control groups in BOO and CP-HC
models (groups 1 and 4) and in animals treated with
PRX (groups 2, 3, 5, 6) ñ after the last PRX dose and
on the day preceding the HRV registration.
HRV records
In groups 1ñ3 HRV was recorded on the day
fifteen (day after the last dose of PRX administered
to animals in groups 2 and 3 and normal saline to
animals in the group 1). In groups 4ñ6 HRV was
recorded on the day eight (after the last dose of CP
and PRX or normal saline). For all rats the HRV reg-
istration was performed under urethane anesthesia
(Sigma Aldrich; 1200 mg/kg b.w.), considering the
literature reports of the relatively lowest effect of
urethane on the autonomic nervous system, com-
pared to other anesthetics (30, 31). After an animal
was anesthetized, shaved and placement of ECG gel,
three disposable electrodes Ag/AgCl (E30, Sorimed,
Poland) were placed in standard places. Two of
them were active electrodes and one a reference, in
order to obtain a single-channel, bipolar record.
During the record, animals were placed under a
heating lamp to prevent chilling that could negative-
ly affect the ANS activity. ECG was registered at
rest for 20 min (Polygram, ADInstruments).
Following registration, records were analyzed for
time- and spectral (frequency) HRV analysis, with
calculation of standard parameters, according to
generally accepted guidelines (26, 27). The time
analysis involved: mean RR [ms] ñ a mean duration
between subsequent R-R waves, maximum and min-
imum duration between subsequent R-R waves
[ms], range of variability of R-R intervals [ms],
mean heart rate [bpm], SDRR ñ standard deviation
of all R-R intervals, and rMSSD ñ square root of
mean sum of differences between R-R waves.
Evaluated in the spectral analysis were: total
power (TP), powers of individual non-normalized
components of the spectrum in the range of very low
frequency (VLF), low frequency (LF), and high fre-
quency (HF); all expressed in power units [ms2],
LF/HF ratio and values of normalized parameters
nLF and nHF (expressed in normalized units [n.u.]).
The following ranges were accepted for individual
components of the spectrum: 0.18 < VLF < 0.28 <
LF < 0.78 < HF < 3.
Collection of bladders
Following HRV recording, animals were sacri-
ficed with a lethal dose of pentobarbital (Morbital,
Pu≥awy, Poland; 100 mg/kg b.w.) for weight and
histopathological analysis of their bladders. The
bladder was collected from each of the study ani-
mals, following a previous separation from the sur-
rounding fatty tissue and voiding. According to the
literature data, measurement of the bladder wet
weight (BWW) may be treated as an indirect evi-
dence of the bladder reconstruction induced by
inflammation (in the CP-HC model) or by outlet
obstruction (in the BOO model), associated with its
overactivity (32ñ34). Directly after collection, blad-
ders were weighed on an analytic scale and then
placed in 4% formalin solution with PBS for further
histopathological evaluation. During the histopatho-
logical procedure, the urinary bladders collected
during autopsy were rinsed in the saline solution.
Next, they were strengthened for 24 h in the 8% for-
malin with phosphate buffer solution (PBS; pH 7.4).
Afterwards, the samples were rinsed in the slow
running water for 2 h, and then they were drained in
the successive growing concentration (50ñ100%) of
ethanol solutions. Before sinking into paraffin, the
samples were moved through both pure xylene solu-
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tion and mixture of xylene and paraffin (1 : 1) and
incubated for 2 h with the maintenance of 37OC.
Next, the individual tissue fragments were moved
twice to clean paraffin and incubated again in tem-
perature 62OC. In the end, after 2 h, the samples
were sunk into blocks and after hardening were cut
using the microtome. The obtained scraps were
placed on the microscopic slides and dried in the
thermostat at 37OC. The finally prepared microscop-
ic sections were stained with hematoxylin eosin
method (HE) to enable the histologic evaluation of
the inflammatory process intensification.
Statistical analysis
Obtained results were analyzed separately for
groups 1ñ3 and 4ñ6 using the Bartlett test, at α =
0.05. Then, paired results were analyzed for groups:
1ñ2, 1ñ3 and 4ñ5, 4ñ6 using the Fischer Snedecor
test at the same α value. Calculated HRV values,
considering lack of their normal distribution, were
converted into logarithmic values (natural loga-
rithms) for the sake of the statistical analysis. 
RESULTS
Body weight and urine volume measurements
At the beginning of the experiment, body
weight of study animals was 188.30 ± 11.83 g. In the
BOO population (group 1), on the day 15 of the
experiment, a mean body weight of study animals
was 203.20 ± 8.58 g, and in the CP-HC model
(group 4), on the day 8 of the study, a day after the
final dose of CP, a mean body weight was reduced
to 181.67 ± 10.62 g, which was associated with poor
general condition of animals in that group.
Before the experiment, healthy rats excreted a
mean volume of 9.50 ± 4.37 mL of urine per day. In
the BOO model (group 1), on the day 14 following
induction of BOO we recorded a mean daily urine
output of 6.90 ± 1.03 mL, and in the CP-HC popula-
tion (group 4), on the day seven following the last
dose of CP ñ 14.83 ± 6.43 mL. Measurements of
daily urine output were intended as an additional,
indirect evidence of the bladder function disorders in
examined models. We did not analyze any precise
changes of those parameters under influence of PRX.
Evaluation of bladder wet weight of collected
bladders
In the BOO group (group 1), on the day 15 of
the experiment, the bladder wet weight achieved
0.26 ± 0.24 g, and in the CP-HC population (group
4), on the day 7 following the last dose of CP ñ 0.17
± 0.04 g. Similarly to the measurement of daily
urine output and according to the above mentioned
literature (32ñ34), the BWW measurement was
intended as an indirect evidence of the bladder func-
tion disorders in particular studied models. The
parameter wasnít also analyzed for effect of PRX.
Therefore, we gave up analogous measurements in
PRX-treated groups.
Conclusions of histological analysis of collected
bladders
According to the pathomorphological evalua-
tion, bladders collected from animals with experi-
mental bladder outlet obstruction (control group of
the BOO model; group 1) demonstrated signs of
edema and congestion of the bladder wall, with a
minimal hyperplasia of the muscular layer. In the
group 4 (control group of the CP-HC model) a clear
edema and signs of congestion (mostly of the cystic
mucosa) were found, and also signs of focal prolif-
eration of fibroblasts in the mucosal lamina propria,
mostly around some fine, submucosal blood
extravasations. Fine lymphocytic inflammatory
infiltrations were visible in vicinity of vessels of the
mucosal lamina propria. Epithelium of the bladder
lining demonstrated focal ulceration with signs of
clear proliferation of cells and of anisonuleosis
focalis et papillosis. The bladder wall muscular coat
was normotypic.
HRV analysis in the BOO model
Time-domain analysis
Parameters of the HRV time analysis were not
significantly different in both groups treated with
PRX and in the control group 1. The population
treated with 2 mg/kg b.w. PRX presented the lowest
value of the mean R-R interval, with the highest
heart rate. Animals treated with the higher dose of
PRX (group 3) demonstrated the highest SDNN
value. Results of the HRV time-domain analysis of
animals in the BOO model are presented in Table 1.
Spectral-domain analysis
Spectral analysis of the BOO model revealed a
trend for reduction of the total power of the spec-
trum and its non-normalized components in both
groups treated with PRX compared to the control
group. Significant differences were observed for
normalized spectral parameters and their mutual
relations ñ in the group 2 (lower PRX dose ) a clear
dominance of nLF was observed with reduction of
the nHF value; in the group 3 (higher PRX dose)
that correlation was precisely reverse.
Results of the HRV spectral analysis of ani-
mals in the BOO model are presented in Table 2.
502 £UKASZ DOBREK et al.






group 1 group 2 group 3parameter
BOO BOO + PRX BOO + PRX 1ñ2 1ñ3
control 2 mg/kg b.w. 10 mg/kg b.w. 
mean RR [ms] 171.80 ± 11.87 160.00 ± 8.53 172.05 ± 6.99 p = 0.01 NS
max RR [ms] 188.32 ± 1.61 178.86 ± 10.79 188.74 ± 1.25 NS NS
min RR [ms] 149.32 ± 18.94 145.45 ± 4.22 145.75 ± 12.57 NS NS
range [ms] 37.10 ± 15.90 33.40 ± 12.94 42.97 ± 12.47 NS NS
average HR [bpm] 351.00 ± 25.31 375.84 ± 18.75 349.18 ± 13.99 p = 0.01 NS
SDNN 7.83 ± 3.95 5.17 ± 3.20 12.52 ± 3.94 NS p = 0.03
rMSSD 7.87 ± 8.34 3.00 ± 4.37 13.31 ± 12.15 NS NS
NS = not significant






group 1 group 2 group 3parameter
BOO BOO + PRX BOO + PRX 1ñ2 1ñ3
control 2 mg/kg b.w. 10 mg/kg b.w. 
TP [ms2] 27.44 ± 33.55 11.23 ± 20.45 18.23 ± 17.84 p = 0.04 NS
VLF [ms2] 22.30 ± 28.95 6.61 ± 15.26 17.42 ± 17.47 p = 0.01 NS
LF [ms2] 2.20 ± 3.26 2.32 ± 3.71 0.52 ± 0.42 NS NS
HF [ms2] 2.94 ± 6.27 2.30 ± 2.53 0.30 ± 0.26 NS NS
LF/HF 0.71 ± 0.58 0.75 ± 0.70 1.85 ± 0.17 NS p = 0.01
nLF [n.u.] 44.81 ± 18.59 35.25 ± 23.27 64.75 ± 2.12 p = 0.01 p = 0.01
nHF [n.u.] 55.19 ± 18.59 64.75 ± 23.27 35.23 ± 2.12 p = 0.01 p = 0.01
NS = not significant
Table 3. Time-domain HRV analysis results in rats with experimental hemorrhagic cystitis evoked by cyclophosphamide (CP-HC) model





group 4 group 5 group 6parameter
CP-HC CP-HC + PRX CP-HC + PRX 4ñ5 4ñ6
control 2 mg/kg b.w. 10 mg/kg b.w. 
mean RR [ms] 160.17 ± 11.23 168.80 ± 14.66 172.77 ± 12.77 NS NS
max RR [ms] 184.92 ± 5.75 188.95 ± 10.08 188.94 ± 10.06 NS NS
min RR [ms] 146.57 ± 8.62 153.63 ± 20.01 147.49 ± 16.40 NS NS
range [ms] 38.36 ± 13.81 35.32 ± 19.97 41.47 ± 16.38 NS NS
average HR [bpm] 376.77 ± 26.16 357.58 ± 30.70 347.90 ± 24.40 NS p = 0.04
SDNN 6.74 ± 2.62 8.80 ± 5.57 10.46 ± 5.17 NS NS
rMSSD 5.48 ± 4.27 14.65 ± 12.97 15.08 ± 10.44 NS p = 0.05
NS = not significant
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HRV analysis in the CP-HC model
Time-domain analysis
Just like in case of the BOO model, parameters
of the HRV time analysis in animals with the CP-
HC model were not significantly different in both
groups treated with PRX and in the control group 2.
All values were comparable in all groups, except for
a mean heart rate in the group 6 ñ the lowest of all
groups, and rMSSD ñ the highest.
Results of the HRV time-domain analysis in
animals in the CP-HC model are presented in Table 3.
Spectral-domain analysis
Contrary to animals in the BOO model (groups
1ñ3), in animals in the CP-HC model treated with
the lower PRX dose (group 5) a trend for increase of
all non-normalized components of the spectrum was
observed, compared to the corresponding control
group. In the group 6 (the higher PRX dose), simi-
larly to groups 2 and 3, TP and HF values were
lower. VLF and LF powers were practically identi-
cal as in the corresponding control group. Both
groups 5 and 6 were characterized by dominance of
the normalized nLF parameter over nHF, and the
difference was statistically significant.
Results of the HRV spectral analysis of ani-
mals in the CP-HC model are presented in Table 4.
DISCUSSION
Considering literature reports, results of daily
urinary output analysis, BWW values and histologi-
cal valuation of collected bladders, a conclusion
could be made that study animals (groups 1 and 4)
meet requirements of bladder outlet obstruction (the
BOO model) and of hemorrhagic cystitis (the CP-
HC model). Hence, we could treat those groups and
their HRV results as control ones, taking them as a
reference for BOO/CP-HC individuals treated with
piroxicam.
The most important conclusions of this study are:
1. Prostaglandins seem to be factors activating
the autonomic nervous system in the model of blad-
der outlet obstruction ñ inhibition of their synthesis
caused a reduction of power of the HRV spectrum
and of its individual non-normalized components:
VLF, LF and HF. The dose of 2 mg/kg b.w. caused
a particular trend for reduction of power in the VLF
range, with marked increase of value of the normal-
ized nHF parameter; the 10 mg/kg b.w. dose caused
mostly a reduction of LF and HF power, but accom-
panied by an increase of the normalized nLF value.
2. In the CP-HC model, the dose of piroxicam
of 2 mg/kg b.w. caused an increase of global activi-
ty of the autonomic nervous system and its non-nor-
malized components. That suggests that a moderate
suppression of prostaglandin synthesis was reflected
by increased activity of the ANS. At the higher PRX
dose the stimulating effect on the ANS functional
condition disappeared, and activity of the ANS was
comparable to the corresponding control group. At
both PRX doses a statistically significant dominance
of the normalized nLF parameter was observed.
We have chosen piroxicam, as an agent inhibit-
ing synthesis of prostaglandins and a non-selective
COX inhibitor for our experiment. Piroxicam (4-
hydroxy-2-methyl-2H-1,2-benzothiazine-1-(N-(2-
pyridinyl)carboxamide)-1,1-dioxide) is a precursor
of the oxicam subgroup in the group of NSAIDs.
The drug was discovered in 1972 and introduced to
Table 4. Spectral-domain HRV analysis results in rats with experimental hemorrhagic cystitis evoked by cyclophosphamide (CP-HC)





group 4 group 5 group 6parameter
CP-HC CP-HC + PRX CP-HC + PRX 4ñ5 4ñ6
control 2 mg/kg b.w. 10 mg/kg b.w. 
TP [ms2] 15.31 ± 15.22 46.77 ± 38.50 13.94 ± 9.49 NS NS
VLF [ms2] 10.00 ± 9.35 27.8 ± 22.01 10.43 ± 6.85 NS NS
LF [ms2] 2.01 ± 2.33 9.37 ± 8.01 2.07 ± 1.81 p = 0.05 NS
HF [ms2] 3.29 ± 3.83 9.61 ± 9.06 1.45 ± 0.98 NS NS
LF/HF 0.71 ± 0.58 1.74 ± 1.35 1.34 ± 0.39 NS NS
nLF [n.u.] 34.42 ± 18.77 57.86 ± 14.86 56.34 ± 6.81 p = 0.04 p = 0.04
nHF [n.u.] 65.52 ± 18.75 42.14 ± 14.86 43.66 ± 6.81 p = 0.04 p = 0.02
NS = not significant
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the medical market by Pfizer in 1982 as a novel ñ for
that time ñ representative of NSAIDs, recommend-
ed particularly to pharmacotherapy of rheumatic
problems (35). Piroxicam is characterized by high
(about 30) COX-1/COX-2 blockade ratio value.
Thus, this compound, together with others common-
ly used in clinical practice drugs, such as ibuprofen,
ketoprofen, diclofenac, naproxen, belongs to
NSAIDs that inhibit both COX-1 and COX-2 with
little selectivity (36). However, comparing to the
other non-selective NSAIDs mentioned above,
piroxicam seems to be relatively the most non-selec-
tive COX-blocking agent. Thus, the pharmacody-
namic profile of piroxicam was the reason of our
choice of PRX in our experiment. Moreover, early
other reports of additional pharmacodynamic prop-
erties of prioxicam appeared as well and other
aspects of the agentsí mechanism of action have
been also discovered. Already in 1983, Ando and
Lombardino (37) demonstrated that PRX inhibited
cellular migration in an inflammatory focus, and sta-
bilized lisosomes of neutrophils, thus counteracting
release of numerous cellular pro-inflammatory
mediators (and of the lymphocytic rheumatoid fac-
tor of the IgM antibody character). Summing up, we
have chosen PRX for the puropose of our study due
to its non-selectivity regarding to COX and potential
additional antiinflammatory effects, even despite the
fact, that this agent is nowadays rarely used in clin-
ical practice (mostly because its gross COX non-
selectivity produces serious adverse effect, such as
unfavorable influence on the digestive tract).
Compared to other NSAIDs, this agent also exerts a
relatively strong ulcerogenic effect (35, 38). That
fact was an impulse for search of new derivatives of
the compound, concluded with discovery of PRX
analogues, including meloxicam, tenoxicam and
lornoxicam, differing from their predecessor not
only in scope of pharmacodynamic properties
(clearly higher selectivity in relation to COX-2), but
also of pharmacokinetic properties (39). 
As mentioned previously in the introduction,
PGs locally synthesized in the bladder intensify its
overreactivity. Therefore, it is expected that
NSAIDs constitute a pharmacologically attractive
group of agents exerting a potentially beneficial
alleviating effect on OAB symptoms. Efficacy of
selected NSAIDs has been confirmed in experimen-
tal studies, and in few ñ so far ñ published clinical
trials. In an experimental model of hemorrhagic cys-
titis induced by a single, large dose of cyclophos-
phamide (150 mg/kg b.w.), Takagi-Matsumoto et al.
(40) demonstrated an improvement of parameters
describing cystometric records in rats, in which the
records were registered during an intravesical
administration of a selected non-selective COX
inhibitor. Those researchers evaluated an effect of
aspirin (0.1ñ10 mg/kg b.w.), indometacin (0.01ñ0.3
mg/kg b.w.) and ketoprofen (0.001ñ0.1 mg/kg b.w.).
Results obtained by them confirmed efficacy of each
of the tested agents in scope of alleviation of cysto-
metric disorders determining OAB in studied indi-
viduals (they observed a reduction of frequency of
micturition episodes and a shift towards the higher
value of threshold micturitional pressure during the
phase of bladder filling). A significant improvement
of cystometric properties of those records was
accompanied by reduction of intravesical PGS level,
evaluated immunoenzymatically in the vesical
supernatant (40). Results of the above experiment
were also confirmed by Jang et al. (41) on a similar
experimental model of OAB, but with use of a selec-
tive COX-2 inhibitor (rofecoxib). Moreover, those
researchers evaluated the nerve growth factor (NGF)
and expression of the induced isoform of nitrogen
oxide synthase (iNOS) content in vesical tissues.
They demonstrated that rats with cyclophos-
phamide-induced chemical bladder injury receiving
rofecoxib at the dose of 2 mg/kg b.w. for one hour,
during the urodynamic record, were characterized
by significantly lower content of both NGF and
iNOS. In opinion of those authors, that results also
in reduced COX-2 expression in bladders of experi-
mental animals when considering physiological
premises: NGF induces activity of COX-2 and pro-
duction of PGs by vesical mastocytes, and increased
enzymatic activity of iNOS and COX-2 depends on
the presence of a common activator of both enzymes
(nitrogen peroxide, formed in the course of NO
metabolism in a focus of inflammation) (41). The
theory of improvement of bladder disturbances as a
result of reduced intravesical PGs synthesis by COX
inhibition has been supported also by Shioyama et
al. (42). Those researchers, using a different OAB
model (chemical damage of the urothelium induced
by intravesical administration of protamine sulfate),
demonstrated that administration of loxoprofen for
two weeks alleviated symptoms of bladder overre-
activity.
There are also few ñ so far ñ published clinical
reports on favorable effect of NSAIDs in OAB phar-
macotherapy. As mentioned before in the introduc-
tion, in the BOO model, reflecting BPH, an increase
of the intravesical PGs level was observed. Saito et
al. (43) demonstrated a significant reduction of
symptoms of bladder overactivity during night in
BPH patients treated with loxoprofen (the drug
caused reduction of nycturia episodes). Similarly,
The influence of piroxicam, a non-selective cyclooxygenase inhibitor, on... 505
Ozdemir et al. (44), evaluating BPH patients treated
with the combined therapy doxazosin and tenoxi-
cam, with use of validated questionnaire scales IPSS
(International Prostate Symptom Scale) and OABSS
(Overactive Bladder Symptom Scale), demonstrated
improvement of their quality of life compared to the
monotherapy with doxazosin.
Summing up, the review of literature confirms
that inhibition of intravesical PGs synthesis with
NSAIDs is associated with alleviation of overactive
bladder symptoms. In our opinion, that favorable
effect may be also ñ at least partially ñ associated
with a change of autonomic regulation of the blad-
der, resulting from disappearance of the modulating
role of prostaglandins. That hypothesis is supported
by our HRV analysis results, particularly the spec-
tral one (time-domain analysis revealed practically
no statistically significant differences between
groups). 
As mentioned above, in the BOO model (cor-
responding to BPH), using both piroxicam doses, we
found a reduction of values of non-normalized spec-
trum components (HF, LF) and of the total power
(TP) of HRV. Additionally, the low PRX dose was
associated with increased power of the normalized
component nHF and a significant reduction of the
VLF value, and the large one ñ with an increase of
the normalized component nLF. On the other hand,
in CP-HC animals (the model clinically correspon-
ding to hemorrhagic, post-cyclophosphamide blad-
der injury), depending on the dosage, we demon-
strated an increase of the spectrum total power and
of its individual non-normalized components (2
mg/kg b.w. PRX), or ñ just like in BOO ñ their
reduction). However, regardless the applied PRX
dose, in that model we observed a statistically sig-
nificant dominance of the normalized parameter
nLF. According to HRV interpretation guidelines
(26, 27), sympathetic activity is expressed mostly by
nLF, parasympathetic ñ reflected by HF and nHF
powers, and the TP value is associated with the
global ANS tonus. There is no general consensus
regarding an unequivocal interpretation of the LF
component ñ a majority of researchers perceive that
parameter as an expression of activity of both arms
of the autonomic system. Even greater controversies
are associated with the VLF component, which ñ in
opinion of majority ñ could be an expression of var-
ious processes associated with hemodynamic regu-
lation dependent on the sympathetic control (26, 27,
45). There is also evidence supporting the hypothe-
sis that VLF reflects the activity of cholinergic anti-
inflammatory pathway, and hence, the component is
of parasympathetic origin (46, 47).
Considering the above guidelines, results
obtained by us from the HRV analysis in the BOO
model suggest that PGs seem to be agents stimulat-
ing global activity of the ANS, since inhibition of
their synthesis causes reduction of the HRV spec-
trum. Evaluating non-normalized spectrum compo-
nents only, it seems that the global reduction is
accompanied by a proportional reduction of activity
of both ANS arms. However, that thesis is negated
by values of normalized parameters nLF and nHF.
In our opinion, lower COX block is expressed main-
ly in reduced sympathetic tonus, as evidenced by
reduction of nLF and VLF (accepting the hypothesis
of a dominating role of the sympathetic component
in generation of power of that component). COX
blockage achieved with the 2 mg/kg b.w. dose and
the functional sympathetic withdrawal contributed
to an increased parasympathetic tonus (nHF
increase), that may still fix symptoms of OAB (high
parasympathetic activity stimulates contractile
activity of the bladder (5)). Five times higher PRX
dose (10 mg/kg b.w.; group 3), with reduction of the
total vegetative reactivity, caused also reorganiza-
tion of the balance within the scope of two essential
components of ANS, with a sympathetic dominance
described by increased nLF, that accounts for reduc-
tion of symptoms of bladder overactivity. High sym-
pathetic activity, associated with activation of β-
adrenergic receptors in the bladder, leads to a
decrease of its contractile activity (5). Therefore,
administration of 10 mg/kg b.w. PRX and inhibition
of PGs synthesis causes changes of autonomic regu-
lation consistent with the above cited reports regard-
ing the alleviating effect of NSAIDs on symptoms
of OAB.
Similar conclusions as those regarding group 3
may be drawn analyzing results of the spectral analy-
sis of animals in the CP-HC model, that received
PRX at the dose of 10 mg/kg b.w. (group 6). Also in
that population, obtained results suggest reduction of
global activity of the ANS, with a vegetative balance
shifted towards the sympathetic component (reduced
TP, HF, nHF values with increased nLF). However,
results obtained in the group of animals with the CP-
HC model but treated with a lower PRX dose (2
mg/kg b.w.; group 5) are debatable. That was the
only subpopulation for which we observed a para-
doxical increase of TP (increase of the ANS total
activity), and of both non-normalized spectral com-
ponents LF and HF (suggesting increase of both
sympathetic and parasympathetic tonus). However,
even in that group we observed identical relations
regarding normalized parameters nLF and nHF, with
a dominance of nLF, suggesting an increased sympa-
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thetic tonus with COX block. We found interpreta-
tion of the fact of increased TP and all non-normal-
ized components : VLF, LF and HF in that model
and at that PRX dose, difficult. Undoubtedly, in that
model, post-cyclophosphamide inflammatory
changes were clearly more intense, compared to
BOO. A lower PRX dose, despite its inhibitory effect
on COX and PGs synthesis, probably was insuffi-
cient to reduce the activating effect of numerous
other pro-inflammatory mediators on the ANS.
Moreover, with increasing PRX dose, an additional,
inhibitory aspect of PRX effect on activity of
immunocompetent cells, as mentioned above, could
appear (37). Therefore, only the higher PRX dose
caused changes similar to those observed in the
BOO model, with establishment of identical rela-
tions between the sympathetic and parasympathetic
activity.
CONCLUSIONS
Summing up, results of our experiment support
the potential efficacy of NSAIDs as PGs synthesis
inhibitors in reduction of bladder overactivity in
both experimental models of OAB (chemical ñ CP-
HC and obstructive ñ BOO), reported in the litera-
ture. In the BOO model, PGs seem to be ANS-acti-
vating factors, and in the CP-HC model ñ they are
undoubtedly co-activators together with other proin-
flammatory mediators. The dose of 10 mg/kg b.w.
of piroxicam in both models caused a reconstruction
of the autonomic balance, with marked sympathetic
dominance, and with simultaneous reduction of total
tonus of the ANS. That suggests that PGs inhibit the
sympathetic activity, and directly or indirectly inten-
sify the parasympathetic activity, contributing to
contractile overactivity of the bladder. Functional
rearrangement of the ANS following inhibition of
PGs synthesis may cause an opposite phenomenon
(reduction of contractile activity of the bladder),
which undoubtedly improves bladder compliance
during its filling.
Of course, we are aware of limitations of our
study (no biochemical and histological studies were
made, that could objectively confirm inhibition of
prostaglandin synthesis and changes in ANS activi-
ty). Therefore, our results have to be treated as pre-
liminary and requiring further clarification.
Moreover, the applied high PRX dose (10 mg/kg
b.w.), exceeding the usually clinical applied dose,
certainly would be a causative factor of severe gas-
tric ulceration and renal damage in humans.
However, in our opinion, supporting the general
concept of beneficial effect of NSAIDs on disorders
associated with OAB, they are valuable, as they
indicate some changes in autonomic regulation as a
possible mechanism of NSAIDs action in OAB.
Moreover, the additional actions of NSAIDs
revealed in our study also provide new insights into
pharmacodynamics aspects of these agents.
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